Investigational drug · Phase 3
Claseprubart
Also called: DNTH103
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myasthenia Gravis, Generalized, Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "Claseprubart"
First trial start
2024
Feb 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Claseprubart", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myasthenia Gravis, Generalized
- Chronic Inflammatory Demyelinating Polyneuropathy
- Multifocal Motor Neuropathy
Approved drugs for the same conditions: Myasthenia gravis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Claseprubart" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)Pivotal-lookingRecruiting
Dianthus TherapeuticsIndustry
NCT06858579 · 256 participants (planned) · Start Feb 10, 2025 · Primary completion Dec 31, 2028
Drug: Claseprubart; Claseprubart and 1 more · For: Chronic Inflammatory Demyelinating Polyneuropathy
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 201 sites in all
- A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)Pivotal-lookingRecruiting
Dianthus TherapeuticsIndustry
NCT07647510 · 195 participants (planned) · Start Jun 29, 2026 · Primary completion Dec 2028
Drug: Claseprubart; Placebo · For: Myasthenia Gravis, Generalized
Sites: Pasadena, California; Boca Raton, Florida; Fayetteville, North Carolina · 12 sites in all
- A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)Active, not recruiting
Dianthus TherapeuticsIndustry
NCT06282159 · 65 participants · Start Feb 23, 2024 · Primary completion Jul 28, 2025
Drug: Claseprubart; Placebo · For: Myasthenia Gravis, Generalized
Sites: Phoenix, Arizona; Irvine, California; Stamford, Connecticut · 56 sites in all
- A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor NeuropathyActive, not recruiting
Dianthus TherapeuticsIndustry
NCT06537999 · 46 participants (planned) · Start Sep 17, 2024 · Primary completion Dec 2026
Drug: Claseprubart; Placebo · For: Multifocal Motor Neuropathy
Sites: Scottsdale, Arizona; Los Angeles, California; Bradenton, Florida · 41 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Myasthenia Gravis, Generalized
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- Descartes-08Phase 24 trials
Cartesian Therapeutics · Myasthenia Gravis, Generalized, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)
- AritinerceptPhase 21 trial
Aurinia Pharmaceuticals Inc. · Myasthenia Gravis, Generalized
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.